Péter Holló - Concepedia

Author

Péter Holló

Also Known As

Holló, Péter, P Holló, P. Hollo, P. Hollò, P. Holló, Paulo Varela, Peter Hollo (7155809), Peter Holló, Peter Humphries, Péter HOLLÓ

192

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Semmelweis University Corvinus University of Budapest University of Debrecen Roswell Park Comprehensive Cancer Center University of Szeged

About

Péter Holló is an author at Semmelweis University specializing in medicine, dermatology, and psoriatic arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	15	1.1K
2	Engineering	1	1	56
3	Health Sciences	1	1	23
4	Public Health	1	1	40
5	Allergy	1	1	34

Péter Holló

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial Thomas Ruzicka, Charles Lynde, Gregor B. E. Jemec, British Journal of Dermatology Severe Che RefractoryOphthalmologyAtopic DermatitisMedicineRetinoic Acid	2008	399
Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial Andrea Vaclavkova, Sergio Chimenti, Petr Arenberger, The Lancet Placebo-controlled Phase 2MedicineClinical TrialsOral PonesimodClinical Dermatology	2014	144
Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary Emese Herédi, Fanni Rencz, Orsolya Balogh, The European Journal of Health Economics Autoimmune DiseaseAtopic DermatitisMedicineEq-5d UtilitiesClinical Dermatology	2014	96
Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: Results of a pilot study Hajnalka Jókai, József Szakonyi, Orsolya Kontár, Journal of the American Academy of Dermatology InflammationMedicineImmunologyFactor-alfa Inhibitor TreatmentClinical Dermatology	2013	87
Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients Adrienn Katalin Poór, Fanni Rencz, Valentin Brodszky, Quality of Life Research Measurement PropertiesPsoriasis PatientsAutoimmune DiseaseMedicineImmunology	2017	74
Road Safety Performance Indicators: Theory. Deliverable D3.6 of the EU FP6 project SafetyNet. Kerstin Auerbach-Hafen, Andrea Hasse, Markus Lerner,	2007	67
Road safety performance indicators and their explanatory value: A critical view based on the experience of Central European countries Péter Holló, Vojtech Eksler, Joanna Żukowska Safety Science Explanatory ValuePublic PolicyTraffic SafetyEngineeringRoad Traffic Safety	2010	56
A detailed analysis of ‘not relevant’ responses on the <scp>DLQI</scp> in psoriasis: potential biases in treatment decisions Fanni Rencz, Adrienn Katalin Poór, Márta Péntek, Journal of the European Academy of Dermatology and Venereology	2017	54
Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis Fanni Rencz, László Gulàcsi, Márta Péntek, British Journal of Dermatology	2018	53
Streptococcus pyogenes–induced cutaneous lymphocyte antigen–positive T cell–dependent epidermal cell activation triggers TH17 responses in patients with guttate psoriasis Ester Ruiz‐Romeu, Marta Ferrán, Marc Sagristà, Journal of Allergy and Clinical Immunology	2016	49

Page 1